July 21, 2009

  • Human Genome Sciences

    Shares of Human Genome Sciences soared Monday on news that the firm's experimental lupus drug showed promise in its latest round of testing. The HGS drug, called Benlysta, must undergo one more major round of testing before the company makes a formal application to the FDA. The biotech firm has partnered with pharmaceutical giant GlaxoSmithKline to market the drug. HGS is slated to get the results of its final Phase 3 test for Benlysta in November. That test will include patients in different geographic regions -- including the United States and Western Europe -- from those used in the most recent tests.

    Source:
    http://www.washingtonpost.com/wp-dyn/content/article/2009/07/20/AR2009072001776.html?hpid=moreheadlines